Thai Senate Debates Potential Impact of EU-Thailand FTA on Public Health
Key points
- Senator Dr.
- Premsak Pia-yura has raised concerns in the Thai Senate regarding the ongoing Free Trade Agreement negotiations with the European Union, specifically citing risks to drug accessibility.
On October 6, 2026, the Thai Senate held a session to discuss the ongoing Free Trade Agreement (FTA) negotiations between Thailand and the European Union. During the proceedings, Senator Dr. Premsak Pia-yura expressed significant concerns regarding the potential long-term consequences of the agreement on the nation's public health system.
Dr. Premsak warned that the government must prioritize public welfare over short-term economic gains. He specifically highlighted the issue of intellectual property rights, suggesting that if the agreement is not carefully managed, it could lead to a monopoly by multinational pharmaceutical corporations. According to the Senator, such a scenario could delay the availability of affordable generic drugs by two to eleven years. Citing public health experts, he noted that drug expenditures in Thailand could rise by at least 130 billion baht within the first decade following the signing of such an agreement.
For residents and those living in Thailand, this debate underscores potential future shifts in healthcare costs and the availability of essential medications. While the Senate is currently reviewing the negotiation framework to protect national interests, the final terms of the FTA remain under discussion. It is not yet confirmed what specific safeguards the government will implement to ensure continued access to affordable healthcare as negotiations with the EU proceed.